Literature DB >> 17617564

Honokiol, a natural plant product, inhibits inflammatory signals and alleviates inflammatory arthritis.

Melissa E Munroe1, Jack L Arbiser, Gail A Bishop.   

Abstract

Honokiol (HNK), a phenolic compound isolated and purified from magnolia, has been found to have a number of pharmacologic benefits, including anti-angiogenic and anti-inflammatory properties. HNK has long been used in traditional Asian medicine without toxic side effects. We and others have extensively studied signaling to B cells by CD40 and its Epstein Barr viral mimic, latent membrane protein 1 (LMP1), which has been implicated in exacerbation of chronic autoimmune disease. We asked whether HNK could inhibit CD40 and LMP1 inflammatory signaling mechanisms. In vivo, HNK stabilized the severity of symptomatic collagen-induced arthritis in both CD40-LMP1 transgenic mice and their congenic C57BL/6 counterparts. Ex vivo studies, including collagen-specific serum Ab and Ag recall responses, as well as CD40 or LMP1-mediated activation of splenic B cells, supported the anti-inflammatory effects of HNK. In mouse B cell lines expressing the human CD40-LMP1 chimeric receptor, CD40- and LMP1-mediated NF-kappaB and AP-1 activation were abrogated in a dose-dependent manner, with a concomitant decrease in TNF-alpha and IL-6. These promising findings suggest that the nontoxic anti-inflammatory properties of HNK could be valuable for blocking the autoimmune response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17617564     DOI: 10.4049/jimmunol.179.2.753

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  Roles of the TRAF2/3 binding site in differential B cell signaling by CD40 and its viral oncogenic mimic, LMP1.

Authors:  John P Graham; Carissa R Moore; Gail A Bishop
Journal:  J Immunol       Date:  2009-08-10       Impact factor: 5.422

Review 2.  Biological activity and toxicity of the Chinese herb Magnolia officinalis Rehder & E. Wilson (Houpo) and its constituents.

Authors:  Mélanie Poivre; Pierre Duez
Journal:  J Zhejiang Univ Sci B       Date:  2017 Mar.       Impact factor: 3.066

Review 3.  Use of Polyphenolic Compounds in Dermatologic Oncology.

Authors:  Adilson Costa; Michael Yi Bonner; Jack L Arbiser
Journal:  Am J Clin Dermatol       Date:  2016-08       Impact factor: 7.403

4.  Latent membrane protein 1, the EBV-encoded oncogenic mimic of CD40, accelerates autoimmunity in B6.Sle1 mice.

Authors:  Anna L Peters; Laura L Stunz; David K Meyerholz; Chandra Mohan; Gail A Bishop
Journal:  J Immunol       Date:  2010-09-01       Impact factor: 5.422

5.  Chaiqin Chengqi Decoction decreases IL-6 levels in patients with acute pancreatitis.

Authors:  Ling Wang; Yuan Li; Qin Ma; Yong Liu; Yuan-yi Rui; Ping Xue; Zong-guang Zhou
Journal:  J Zhejiang Univ Sci B       Date:  2011-12       Impact factor: 3.066

6.  Anti-inflammatory effects of the neurotransmitter agonist Honokiol in a mouse model of allergic asthma.

Authors:  Melissa E Munroe; Thomas R Businga; Joel N Kline; Gail A Bishop
Journal:  J Immunol       Date:  2010-10-01       Impact factor: 5.422

7.  The Effects of Rhein and Honokiol on Metabolic Profiles in a Mouse Model of Acute Pancreatitis.

Authors:  Wei Huang; Hang Liu; Yu Li; Gang Mai
Journal:  Med Sci Monit       Date:  2020-10-23

8.  A novel polymorphism of the human CD40 receptor with enhanced function.

Authors:  Anna L Peters; Robert M Plenge; Robert R Graham; David M Altshuler; Kathy L Moser; Patrick M Gaffney; Gail A Bishop
Journal:  Blood       Date:  2008-06-30       Impact factor: 22.113

Review 9.  Honokiol, a multifunctional antiangiogenic and antitumor agent.

Authors:  Levi E Fried; Jack L Arbiser
Journal:  Antioxid Redox Signal       Date:  2009-05       Impact factor: 8.401

10.  Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function.

Authors:  Courtney Crane; Amith Panner; Russell O Pieper; Jack Arbiser; Andrew T Parsa
Journal:  J Immunother       Date:  2009 Jul-Aug       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.